Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-in-Pentetreotide. Addendum
Chung G, Rimm D. Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-in-Pentetreotide. Addendum. 2008 DOI: 10.21236/ada487987.Peer-Reviewed Original ResearchBreast cancerTissue microarrayPredominant receptor subtypeWhole section analysisBenign breast tissueHeterogeneity of expressionSSTR2 levelsProgression of cancerTargeted therapyReceptor subtypesSomatostatin receptorsClinical significanceLymphatic elementsCo-localization techniquesCell line controlMalignant cellsSSTR2Breast tissueCancerPattern of expressionProtein expressionPeptide hormonesVessel compartmentReference standard curveSomatostatin